Tempus AI, Inc. (NASDAQ:TEM) Short Interest Update

Tempus AI, Inc. (NASDAQ:TEM) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 8,730,000 shares, an increase of 42.2% from the December 15th total of 6,140,000 shares. Currently, 17.8% of the shares of the stock are short sold. Based on an average trading volume of 2,340,000 shares, the short-interest ratio is currently 3.7 days.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on TEM shares. Guggenheim began coverage on Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective on the stock. Loop Capital dropped their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday. Wolfe Research began coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Bank of America lifted their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Finally, Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and upped their price target for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Tempus AI presently has an average rating of “Moderate Buy” and a consensus target price of $56.36.

Tempus AI Stock Down 0.5 %

Tempus AI stock traded down $0.17 during midday trading on Thursday, reaching $34.75. The stock had a trading volume of 2,743,470 shares, compared to its average volume of 4,066,956. The company has a fifty day moving average price of $47.24 and a two-hundred day moving average price of $47.17. Tempus AI has a 12 month low of $22.89 and a 12 month high of $79.49. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Insider Transactions at Tempus AI

In other news, EVP Andrew Polovin sold 51,504 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the completion of the transaction, the executive vice president now owns 246,085 shares of the company’s stock, valued at approximately $10,431,543.15. The trade was a 17.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total value of $16,999,610.00. Following the sale, the insider now owns 16,164,449 shares of the company’s stock, valued at approximately $694,263,084.55. This represents a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 865,041 shares of company stock valued at $35,917,673.

Hedge Funds Weigh In On Tempus AI

A number of institutional investors have recently modified their holdings of the company. Kovitz Investment Group Partners LLC bought a new position in shares of Tempus AI in the third quarter valued at $1,367,000. Sumitomo Mitsui Trust Group Inc. lifted its position in Tempus AI by 1,591.2% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after acquiring an additional 1,145,698 shares in the last quarter. Captrust Financial Advisors acquired a new position in Tempus AI during the 3rd quarter valued at about $2,726,000. Dakota Wealth Management bought a new stake in Tempus AI during the 3rd quarter worth approximately $1,185,000. Finally, Sigma Planning Corp purchased a new stake in shares of Tempus AI in the third quarter worth approximately $1,323,000. 24.22% of the stock is owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.